Q-omics provides the consensus-scored HYAL6P profile across patient tissues and cancer cell-line models. HYAL6P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, HYAL6P is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, HYAL6P RNA expression shows 9,776 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, KIRC, and TGCT as cancer lineages where HYAL6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HYAL6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HYAL6P survival associations across molecular data types. HYAL6P RNA expression shows survival associations in the most cancer types (15), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HYAL6P RNA expression–survival associations across cancer types. High HYAL6P expression shows unfavorable associations in COAD, ACC, THYM, THCA and UVM, but favorable associations in SKCM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for HYAL6P RNA expression.
This table summarizes HYAL6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HYAL6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HYAL6P shows lower tumor expression in KIRC, KIRP and THCA. The KIRC box plot shows higher HYAL6P RNA expression in normal versus tumor tissue (log2 FC = −0.220, t-test p < 0.001).
This table shows molecular features associated with HYAL6P in patient tissues and cancer cell lines. In patient samples, HYAL6P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
